This shows you the differences between two versions of the page.
Both sides previous revisionPrevious revisionNext revision | Previous revision | ||
home:othertreatments:antitnf [10.24.2009] – external edit 127.0.0.1 | home:othertreatments:antitnf [09.14.2022] (current) – external edit 127.0.0.1 | ||
---|---|---|---|
Line 1: | Line 1: | ||
====== Anti-TNF drugs ====== | ====== Anti-TNF drugs ====== | ||
- | <html>< | + | <relatedarticle> [[home: |
- | Tumor necrosis factor-alpha or TNF-alpha is a cytokine critical for effective immune surveillance and is required for proper proliferation and function of natural killer cells, T cells, B cells, macrophages, | + | Tumor necrosis factor-alpha or TNF-alpha is a cytokine critical for effective immune surveillance and is required for proper proliferation and function of natural killer cells, T cells, B cells, macrophages, |
- | Anti-TNF drugs are expensive, ineffective at treating chronic disease and have a number of adverse effects. | + | Anti-TNF drugs are expensive, ineffective at treating chronic disease and have a number of adverse effects. |
- | + | ||
- | Anti-TNF drugs can make a patient feel temporarily less symptomatic, | + | |
Line 23: | Line 21: | ||
During immunopathology, | During immunopathology, | ||
- | The release of cytokines appears to be essential for recovery after an infection. One study found that the cytokine TNF-alpha is necessary for the proper expression of acquired specific resistance following infection with // | + | The release of cytokines appears to be essential for recovery after an infection. One study found that the cytokine TNF-alpha is necessary for the proper expression of acquired specific resistance following infection with // |
For these reasons among others, TNF-alpha inhibitors, drugs which suppress the cytokine, are contraindicated for MP patients. | For these reasons among others, TNF-alpha inhibitors, drugs which suppress the cytokine, are contraindicated for MP patients. | ||
Line 30: | Line 28: | ||
==== Olmesartan (Benicar) vs. TNF-alpha blockers ==== | ==== Olmesartan (Benicar) vs. TNF-alpha blockers ==== | ||
- | <html>< | + | <relatedarticle> [[home: |
Line 48: | Line 46: | ||
===== Increased risk of infection ===== | ===== Increased risk of infection ===== | ||
- | One recent systematic review of the adverse effects of anti-TNF therapies as they were used in rheumatoid arthritis concluded that patients taking the drugs are at 2.0 times higher risk for serious infections.(({{pubmed> | + | One recent systematic review of the adverse effects of anti-TNF therapies as they were used in rheumatoid arthritis concluded that patients taking the drugs are at 2.0 times higher risk for serious infections.(({{pmid> |
- | [[http:// | + | [[https://google2.fda.gov/ |
< | < | ||
- | //**U.S. Food and Drug Administration**//, | + | //**U.S. Food and Drug Administration**//, |
- | //M. tuberculosis// | + | //M. tuberculosis// |
< | < | ||
- | //**M.A. Gardman** et al//(({{pubmed> | + | //**Michael |
- | To reduce the likelihood of contracting or exacerbating tuberculosis, | + | To reduce the likelihood of contracting or exacerbating tuberculosis, |
- | Fatal fungal | + | " |
Researchers have also observed reactivation of latent viral infections, namely hepatitis B in patients who are chronic carriers of the virus. | Researchers have also observed reactivation of latent viral infections, namely hepatitis B in patients who are chronic carriers of the virus. | ||
- | For these reasons, physicians are [[http:// | + | For these reasons, physicians are [[https:// |
===== Other adverse effects ====== | ===== Other adverse effects ====== | ||
- | * **Allergic reaction** – Some patients report an allergic response to Remicade. One possible reason may be that the [[http:// | + | * **Allergic reaction** – Some patients report an allergic response to Remicade. One possible reason may be that the [[https:// |
* **Congestive heart failure** – Exacerbation of CHF is a major side effect of Remicade use in patients with moderate to severe CHF. This is especially problematic in that many sarcoidosis patients do not know that they have cardiac involvement. | * **Congestive heart failure** – Exacerbation of CHF is a major side effect of Remicade use in patients with moderate to severe CHF. This is especially problematic in that many sarcoidosis patients do not know that they have cardiac involvement. | ||
- | * **Liver problems** – [[http:// | + | * **Liver problems** – [[https:// |
- | * **Skin problems** – In one prospective trial, 25% of patients on TNF-alpha-blocking therapy suffered from a dermatological condition that led them to visit a skin specialist. In a control group of patients who were not undergoing TNF-alpha blocking therapy and had less severe disease only 13% visited a dermatologist during the same period of time.(({{pubmed> | + | * **Skin problems** – In one prospective trial, 25% of patients on TNF-alpha-blocking therapy suffered from a dermatological condition that led them to visit a skin specialist. In a control group of patients who were not undergoing TNF-alpha blocking therapy and had less severe disease only 13% visited a dermatologist during the same period of time.(({{pmid> |
- | * **Cancer** – One recent systematic review of the adverse effects of anti-TNF therapies as they were used in rheumatoid arthritis concluded that patients taking the drugs are at 3.3 times higher risk for " | + | * **Cancer** – One recent systematic review of the adverse effects of anti-TNF therapies as they were used in rheumatoid arthritis concluded that patients taking the drugs are at 3.3 times higher risk for " |
Line 86: | Line 84: | ||
Considering that Abbott’s Humira was the company’s best-selling product in 2007 with over $3 billion in sales, and Remicade also topped Schering-Plough’s portfolio with sales of $1.65 billion, there is minimal hope that such companies will be willing to embrace a true understanding of how their drugs foster the development of chronic disease. | Considering that Abbott’s Humira was the company’s best-selling product in 2007 with over $3 billion in sales, and Remicade also topped Schering-Plough’s portfolio with sales of $1.65 billion, there is minimal hope that such companies will be willing to embrace a true understanding of how their drugs foster the development of chronic disease. | ||
- | Insurance coverage and baseline cost of anti-TNF drugs varies, but patients in the United States and Canada [[http:// | + | Insurance coverage and baseline cost of anti-TNF drugs varies, but patients in the United States and Canada [[https:// |
- | One citizen watchdog group, the New Jersey Citizen Action (NJCA), [[http:// | + | One citizen watchdog group, the New Jersey Citizen Action (NJCA), [[https:// |
Line 98: | Line 96: | ||
{{tag> }} | {{tag> }} | ||
+ | < | ||
===== Notes and comments ===== | ===== Notes and comments ===== | ||
- | EDIT | + | |
* Legacy content | * Legacy content | ||
- | * http:// | + | * https:// |
- | ===== References ===== | + | ===== References =====</ |